BD Biosciences/CD14 APC-Cy™7/333951,BD Biosciences,,BD Biosciences,bdbiosciences,+,,Array.Array.Array蚂蚁淘厂家直采.

产品名称：BD Biosciences/CD14 APC-Cy™7/333951

产品编号：333951

市场价：¥0.00

场地：美国(厂家直采)

产品分类：蛋白类>多肽>多肽合成>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： BD Biosciences

公司：BD Biosciences,Inc.

公司分类：

商品介绍

Product DetailsRecommended AssayReferences

Description

CD14 is intended for in vitro diagnostic use in the identification of cells expressing CD14 antigen, using a BD FACS™ brand flow cytometer.

The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software (such as BD CellQuest™ or BD LYSYS™ II software) for data acquisition and analysis. Refer to your instrument user’s guide for instructions.

Format

FormatAPC-Cy™7
Excitation SourceRed 633 nm
Excitation Max650nm
Emission Max785nm

APC-Cy™7 is a tandem fluorochrome that combines APC and a cyanine dye (Cy7). Special precautions must be taken with APC-Cy7 conjugates, and cells stained with them, to protect the fluorochrome from long-term exposure to light. Some APC-Cy7 conjugates show changes in their emission spectra with prolonged exposure to paraformaldehyde. Fixed cells should be analyzed within 4 hours of fixation in paraformaldehyde or transferred to a paraformaldehyde-free buffer for overnight storage. Due to nearly identical excitation and emission properties but different spillover characteristics, APC-Cy7 and APC-H7 cannot be used simultaneously.

Resources & Tools
Spectrum Viewer	Panel Designer	SpectrumViewer	Download TDS	CFDA License	Download MSDS

Preparation and Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. H42-A2.
Protection of Laboratory Workers from Occupationally Acquired Infections–Second Edition; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 2001. NCCLS document M29-A2.
Bernard A, Boumsell L, Hill C. Joint report of the First International Workshop on Human Leucocyte Differentiation Antigens by the investigators of the participating laboratories: In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, eds. Leucocyte Typing. New York, NY: Springer-Verlag; 1984:82-108.
Bernstein ID, Self S. Joint report of the myeloid section of the Second International Workshop on Human Leukocyte Differentiation Antigens. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human Myeloid and Hematopoietic Cells. New York, NY: Springer-Verlag; 1986;3:1-25.
Callea V, Marabito F, Oliva BM, et al. Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome. Br J Haematol. 1999;107:347-352.
Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.
Dimitriu-Bona A, Burmester GR, Waters SJ, Winchester RJ. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol. 1983;130:145-152.
Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991;5:637-645.
Drexler HG. Classification of acute myeloid leukemias: a comparison of FAB and immunophenotyping. Leukemia. 1987;1:697-705.
Goyert SM, Ferrero E. Biochemical analysis of myeloid antigen and cDNA expression of gp55 (CD14). In: McMichael AJ, ed. Leucocyte Typing III: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1987:613-619.
Hansen I, Meyer K, Hokland P. Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol. 1998;61:339-346.
Herrmann F, Komischke B, Odenwald E, Ludwig WD. Use of monoclonal antibodies as a diagnostic tool in human leukemia. I. Acute myeloid leukemia and acute phase of chronic myeloid leukemia. Blut. 1983;47:157-163.
Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.
Jayaram Y, Hogg N. Surface expression of CD14 molecules on human neutrophils. In: Knapp W, Dörken B, Gilks WR, et al., eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:796-797.
Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998;109:211-220.
Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.
Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.
Ziegler-Heithbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today. 1993;14:121-125.

品牌介绍

BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。

公司介绍

更多...

产品分类

更多...